These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37896130)

  • 1. A Reversibly Thermoresponsive, Theranostic Nanoemulgel for Tacrolimus Delivery to Activated Macrophages: Formulation and In Vitro Validation.
    Vichare R; Crelli C; Liu L; Das AC; McCallin R; Zor F; Kulahci Y; Gorantla VS; Janjic JM
    Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the Pill Burden: Immunosuppressant Adherence and Safety after Conversion from a Twice-Daily (IR-Tac) to a Novel Once-Daily (LCP-Tac) Tacrolimus Formulation in 161 Liver Transplant Patients.
    Maurer MM; Ibach M; Plewe J; Winter A; Ritschl P; Globke B; Öllinger R; Lurje G; Schöning W; Pratschke J; Eurich D
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
    Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
    Transpl Int; 2022; 35():10225. PubMed ID: 36017158
    [No Abstract]   [Full Text] [Related]  

  • 4. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score.
    Almond CS; Sleeper LA; Rossano JW; Bock MJ; Pahl E; Auerbach S; Lal A; Hollander SA; Miyamoto SD; Castleberry C; Lee J; Barkoff LM; Gonzales S; Klein G; Daly KP
    Am Heart J; 2023 Jun; 260():100-112. PubMed ID: 36828201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Safety and Tolerability Study of Thin Film Freeze-Dried Tacrolimus for Local Pulmonary Drug Delivery in Human Subjects.
    Sahakijpijarn S; Beg M; Levine SM; Peters JI; Williams RO
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34068391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoemulgel, an Innovative Carrier for Diflunisal Topical Delivery with Profound Anti-Inflammatory Effect: in vitro and in vivo Evaluation.
    Bashir M; Ahmad J; Asif M; Khan SU; Irfan M; Y Ibrahim A; Asghar S; Khan IU; Iqbal MS; Haseeb A; Khalid SH; As Abourehab M
    Int J Nanomedicine; 2021; 16():1457-1472. PubMed ID: 33654396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism.
    Uchida J; Kuwabara N; Machida Y; Iwai T; Naganuma T; Kumada N; Nakatani T
    Transplant Proc; 2012 Jan; 44(1):128-33. PubMed ID: 22310596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternatives to immediate release tacrolimus in solid organ transplant recipients: When the gold standard is in short supply.
    Jorgenson MR; Descourouez JL; Brady BL; Bowman L; Hammad S; Kaiser TE; Laub MR; Melaragno JI; Park JM; Chandran MM
    Clin Transplant; 2020 Jul; 34(7):e13903. PubMed ID: 32400907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Injections of Tacrolimus-loaded Hydrogel Reduce Systemic Immunosuppression-related Toxicity in Vascularized Composite Allotransplantation.
    Dzhonova DV; Olariu R; Leckenby J; Banz Y; Prost JC; Dhayani A; Vemula PK; Voegelin E; Taddeo A; Rieben R
    Transplantation; 2018 Oct; 102(10):1684-1694. PubMed ID: 29794937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily tacrolimus extended-release formulation: 1-year post-conversion in stable pediatric liver transplant recipients.
    Heffron TG; Pescovitz MD; Florman S; Kalayoglu M; Emre S; Smallwood G; Wisemandle K; Anania C; Dhadda S; Sawamoto T; Keirns J; Fitzsimmons W; First MR
    Am J Transplant; 2007 Jun; 7(6):1609-15. PubMed ID: 17511684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Conversion to Once-Daily Tacrolimus from Twice-Daily Tacrolimus in Pediatric Liver Transplant Recipients.
    An S; Lee S; Rhu J; Kim JM; Choi GS; Joh JW
    J Pediatr Surg; 2023 Oct; 58(10):2054-2058. PubMed ID: 37277238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs.
    Sengupta P; Chatterjee B
    Int J Pharm; 2017 Jun; 526(1-2):353-365. PubMed ID: 28461261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus-Eluting Disk within the Allograft Enables Vascularized Composite Allograft Survival with Site-Specific Immunosuppression without Systemic Toxicity.
    Feturi FG; Unadkat JV; Zhang W; Hag ME; Wang Y; Komatsu C; Grybowski D; Zhang Z; Erbas V; Sahin H; Mcclaine S; Oksuz S; Plock J; Gorantla VS; Washington KM; Solari MG; Venkataramanan R; Spiess AM
    Pharm Res; 2022 Sep; 39(9):2179-2190. PubMed ID: 35915321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.